A Phase I Open-Label, Dose-Escalation and Dose-Expansion Trial Evaluating Safety, Pharmacokinetics, and Efficacy of HW071021 in Patients with Advanced Solid Tumors
Latest Information Update: 27 Mar 2025
At a glance
- Drugs HW 071021 (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Humanwell Healthcare
- 27 Mar 2025 New trial record